Pembrolizumab plus single-agent chemotherapy as first-line treatment for advanced non-small cell lung cancer in patients with ECOG performance status 2

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, first-line combination trial enrolling adults with histologically confirmed stage IIIc or IV non-small cell lung cancer who have an ECOG performance status of 2. Participants receive pembrolizumab together with a single chemotherapy agent (options include pemetrexed or nab-paclitaxel) and are followed for safety, tolerability, and early signs of anti-tumor activity. Eligibility requires basic blood and kidney function thresholds and allows small, asymptomatic brain metastases. The design aims to define whether this combination can be delivered safely to patients who are not candidates for standard platinum-doublet therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants must be \>18 years old at time of diagnosis
2. Histologically confirmed non-small cell lung cancer
3. ECOG PS 2
4. Clinical staging of IIIc or IV disease.

4A. For patients with stage IIIc disease, patients are ineligible for or refuse standard treatment with platinum-double chemotherapy and radiation.

4B. For patients with stage IV disease, platinum doublet chemotherapy is not appropriate, deemed unsafe by the treating physician, or declined by the patient

4C. Screening lab work must meet the following parameters:

4Ca. Absolute neutrophil count (ANC) ≥1000/mm3

4Cb. Platelet count ≥100,000/mm3

4Cc. CrCl\>50 (if pemetrexed is to be offered)

4Cd. AST and ALT ≤ 2.5 x ULN

4D. Patients with small, asymptomatic brain metastases are eligible

4E. Women of childbearing potential must be negative for pregnancy testing (urine or blood) and agree to use effective contraception. Viable contraception should be used after trial screening, before initiation of chemotherapy, and throughout the duration of active treatment in the study.

Non-childbearing potential is defined as (by other than medical reasons): -Amenorrheic \>2 years

* Amenorrheic for \<2 years and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation
* Post hysterectomy, oophorectomy or tubal ligation. Otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study drug

  4F.Participants must read or be read and explained the purposes of the study and sign a statement of informed consent prior to participation. Those who do not read or understand English are eligible and may be consented according to institutional regulations.

Exclusion Criteria:

1. Patients with history of autoimmune conditions with the following exceptions, which are allowed: alopecia, vitiligo, rheumatoid arthritis, psoriasis/psoriatic arthritis, Hashimoto's thyroiditis
2. Patients on immunosuppressive medication, including steroids (if doses exceed equivalent of prednisone 10 mg daily). Short courses of steroids which are discontinued prior to start of treatment are acceptable.
3. Patients with cardiovascular, hepatic, or renal systemic diseases that would preclude use of chemotherapy and/or immunotherapy per the treating investigator.
4. The patient must not be on any clinical trials involving other experimental therapies during study treatment
5. Women who are currently pregnant or breast-feeding
6. Patients with any other concurrent medical or psychiatric condition that were deemed inappropriate for entry into the study per the investigator.
7. Symptomatic, untreated brain metastases. Patients with treated brain metastases may be considered eligible after completion of radiation if steroids have been tapered to less than equivalent of 10 mg of prednisone.
8. Active infection requiring IV antibiotics

Where it's running

• University of Rochester
  Rochester, New York, United States Recruiting
• University of Rochester
  Rochester, New York, United States Not yet recruiting

Study contacts

• Principal investigator: Megan Baumgart — University of Rochester
• Study coordinator: Megan Baumgart
• Email: Megan_Baumgart@URMC.Rochester.edu
• Phone: 585-275-4401

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• ABBV-1480 plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer

  This study tests whether ABBV-1480 with platinum-based chemotherapy can work better than pembrolizumab with chemotherapy for adults with certain stages of non-small cell lung cancer.

  Recruiting at 2 sites Phase 3 AbbVie · Fort Wayne, Indiana and 1 other locations · NCT07756645

• Adjuvant intismeran (V940) with or without pembrolizumab plus berahyaluronidase alfa for high‑risk Stage I non‑small cell lung cancer after surgery

  This trial will try intismeran (V940) alone or together with subcutaneous pembrolizumab plus berahyaluronidase alfa to help prevent recurrence in people with completely removed high‑risk Stage I non‑small cell lung cancer.

  Recruiting at 126 sites Phase 3 Merck Sharp & Dohme LLC · Sacramento, California and 125 other locations · NCT07513376

• Adjuvant calderasib with subcutaneous pembrolizumab plus berahyaluronidase alfa for completely resected KRAS G12C stage IIA–IIIB (N2) NSCLC

  This trial tests whether adding the oral KRAS G12C inhibitor calderasib to subcutaneous pembrolizumab plus berahyaluronidase alfa helps prevent recurrence in people with completely resected stage IIA–IIIB (N2) KRAS G12C non‑small cell lung cancer.

  Recruiting at 122 sites Phase 3 Merck Sharp & Dohme LLC · Ciudad Autónoma de Buenos Aires, Buenos Aires and 121 other locations · NCT07431827

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Calderasib plus subcutaneous pembrolizumab for KRAS G12C non-small cell lung cancer

  This trial will test whether adding the KRAS G12C drug calderasib to subcutaneous pembrolizumab helps people with advanced nonsquamous non‑small cell lung cancer live longer without the cancer growing compared with pembrolizumab plus chemotherapy.

  Recruiting at 221 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 224 other locations · NCT07190248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.